WAVEMAN · COMPANY

INM · Inmed Pharmaceuticals Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

INM

Name: InMed Pharmaceuticals Inc. (INM) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

InMed Pharmaceuticals Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001728328

CLUSTER · 3 INSIDERSACTIVIST 13D☆ WATCH

INSIDER NET · 180D

$1.2M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+7.5%

XBRL, annual

NET MARGIN

-165.1%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$1.2M over 180 days

+$92.9K over 90 days · +$1.2M of it by a 10%+ holder

more than 89% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

13 funds added or opened last quarter

below 78% of Pharma & Biotech

REVENUE

+7.5% year over year

more than 58% of Pharma & Biotech

MARGIN

-165.1% net margin

below 70% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

2.5% of shares outstanding short · 1.0 days to cover · settled 2026-07-31

below 60% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

3 insiders independently bought a net $1.2M — no planned sales are queued against it.

Vivo Opportunity Fund Holdings, L.P. disclosed a 5%+ stake (21.7%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -36.1%

-36.1%12M

INSIDER BUY13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

3 insiders reported buying shares.

The record shows a net $1.2M bought by insiders over 180 days, 13 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, InMed Pharmaceuticals Inc. insiders bought a net $1.2M of stock across 46 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Vivo Opportunity, LLC

—

BUY

2026-07-16

19.0

$29

Vivo Opportunity, LLC

—

BUY

2026-07-16

2.0

ADAR1 Capital Management, LLC

—

BUY

2026-07-15

1,000.0

$1.6K

Vivo Opportunity, LLC

—

BUY

2026-07-15

13,761.0

$21.3K

Vivo Opportunity, LLC

—

BUY

2026-07-15

1,389.0

$2.2K

46 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 41 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

ADAR1 Capital Management, LLC

800,000.0 sh

$1.2M

Vivo Capital, LLC

798,377.0 sh

$1.2M

Squadron Capital Management LLC

325,000.0 sh

$503.8K

Ikarian Capital, LLC

245,025.0 sh

$379.8K

Ursa Fund Management, LLC

125,800.0 sh

$195.0K

5%+ owners

13D = intent to influence · 13G = passive

Vivo Opportunity Fund Holdings, L.P.

ACTIVIST 13D · 2026-06-10

21.7%

Vivo Opportunity, LLC

ACTIVIST 13D · 2026-06-10

21.7%

Vivo Opportunity Cayman Fund, L.P.

ACTIVIST 13D · 2026-06-10

2.2%

Vivo Opportunity Cayman, LLC

ACTIVIST 13D · 2026-06-10

2.2%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Clinical pipeline

ClinicalTrials.gov · 1 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-06	2024-06	2023-06	2022-06
REVENUE	$4.9M	$4.6M	$4.1M	$1.1M
GROSS PROFIT	$1.7M	$1.1M	$1.4M	$543.5K
OPERATING INCOME	—	—	$-7.9M	$-18.6M
NET INCOME	$-8.2M	$-7.7M	$-7.9M	$-18.6M
EPS (DILUTED)	-8.36	-20.14	-3.25	-33.17
OPERATING CASH FLOW	$-7.8M	$-7.0M	$-7.3M	$-15.6M
CASH	$11.1M	$6.6M	$8.9M	$6.2M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE